key: cord-0915491-n3lrzw3o
authors: Beavis, Kathleen G.; Matushek, Scott M.; Abeleda, Ana Precy F.; Bethel, Cindy; Hunt, Carlissa; Gillen, Stephanie; Moran, Angelica; Tesic, Vera
title: Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies
date: 2020-05-23
journal: J Clin Virol
DOI: 10.1016/j.jcv.2020.104468
sha: 2f8a62f658f664b3cd82a0372f7e5a4e5fd518c4
doc_id: 915491
cord_uid: n3lrzw3o

As the Coronavirus 2019 (COVID-19) pandemic evolves, the development of immunoassays to help determine exposure and potentially predict immunity has become a pressing priority. In this report we present the performance of the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgA and IgG antibodies in serum and plasma samples using recombinant S1 domain of the SARS-CoV-2 spike protein as antigen. Specimens from patients, with and without COVID-19 infection, were tested at the University of Chicago Clinical Microbiology and Immunology Laboratory. Of 86 samples from COVID-19 PCR-negative patients, including 28 samples positive for common human coronavirus strains, 76 tested negative and 10 tested positive for IgA (88.4% agreement, 95% CI: 79.9–93.6) while 84 tested negative and 2 tested positive for IgG (97.7% agreement, 95% CI: 91.9–99.6). Of 82 samples from COVID-19 PCR-positive patients, 14 tested negative and 68 tested positive for IgA (82.9% agreement, 95% CI: 73.4–89.5) while 27 tested negative and 55 tested positive for IgG (67.1% agreement, 95% CI: 56.3–76.3). Samples collected ≥4 days after positive PCR 38 of 42 (90.5% CI: 77.9–96.2) were positive for IgA, and 42 of 42 (100% 95% CI: 91.6–100) were positive for IgG, respectively. The EUROIMMUN Anti-SARS-CoV-2 ELISA Assay demonstrates good sensitivity for detection of IgA and excellent sensitivity for detection of IgG antibodies from samples collected ≥4 days, after COVID-19 diagnosis by PCR. This assay demonstrated only borderline cross reaction in 2 of the 28 samples from patients with common human coronaviruses infection, types NL63 and OC43.

As the Coronavirus 2019 (COVID-19) pandemic evolves, the development of immunoassays to help determine exposure and potentially predict immunity has become a pressing priority. In this report we present the performance of the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgA and IgG antibodies in serum and plasma samples using recombinant S1 domain of the SARS-CoV-2 spike protein as antigen. Specimens [2] . IgA antibodies can show higher sensitivity, while IgG antibodies typically have longer duration, better specificity, and are better suited for serosurveillance studies [3] [4] [5] .

The EUROIMMUN Anti-SARS-CoV-2 assay is an enzyme-linked immunosorbent assay The Cepheid Xpert Xpress SARS-CoV-2 assay also detects the pan-sarbecovirus Egene but uses the SARS-CoV-2 specific N-gene rather than ORF1 as its primary target. Limitations of this study include a small sample size and a lack of specimens collected more than 49 days following a positive PCR. 

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv 04

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARSassociated coronavirus

Evaluation of nine commercial SARS-CoV-2 immunoassays

Anti-SARS-CoV-2 ELISA IgG, Package insert. EI_2606G_A_US_C02.docx Version

Anti-SARS-CoV-2 ELISA IgA, Package insert.EI_2606A_A_US_C01.docx Version

Occupational Medicine at the University of Chicago.

All authors declared No conflict of interest.